Graft-versus-leukaemia effect in children: Chronic GVHD has a significant impact on relapse and survival

Bone Marrow Transplantation

Volumn 31, Issue 3, 2003, Pages 175-181

  Gustafsson Jernberg, A ^a   Remberger, M ^a   Ringden O ^a   Winiarski, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bone marrow transplantation; Children graft versus host disease; Graft versus leukaemia; Relapse survival

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; METHOTREXATE; METHYLPREDNISOLONE; OKT 3; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ALLOTRANSPLANTATION; ARTICLE; CANCER CENTER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; STATISTICAL MODEL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PREDICTIVE VALUE OF TESTS; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037294597     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703808     Document Type: Article

References (39)

1. Thomas ED, Sanders JE, Flournoy N et al. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood 1979; 54: 468-476.
2. Gustafsson A, Remberger M, Winiarski J et al. Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting. Bone Marrow Transplant 2000; 25: 1059-1065.
3. Barnes AD. Treatment of murine leukaemia with X-rays and homologous bone marrow. Br Med J 1957; 3: 241-252.
4. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068-1073.
5. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
6. Woods WG, Neudorf S, Gold S et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.
7. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
8. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
9. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
10. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
11. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-578.
12. Ringden O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
13. Ringden O, Backman L, Lonnqvist B et al. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986; 1: 41-51.
14. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
15. Ljungman P, Lore K, Aschan J et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583-587.
16. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Thomas ED, Blume KG, Forman SJ. Hematopoietic Stem Cell Transplantation, 2nd edn. Blackwell Science, Inc.: Malden, MA, USA, 1998.
18. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
19. Carlens S, Ringden O, Remberger M et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998; 22: 755-761.
20. Winiarski J, Ringden O, Remberger M et al. Bone marrow transplantation in children using unrelated donors at Huddinge Hospital. Acta Paediatr 1996; 85: 327-335.
21. Amadori S, Testi AM, Arico M et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 1993; 11: 1046-1054.
22. Barrett AJ, Horowitz MM, Pollock BH et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994; 331: 1253-1258.
23. Doney K, Fisher LD, Appelbaum FR et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991; 7: 453-459.
24. Weisdorf DJ, Nesbit ME, Ramsay NK et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. J Clin Oncol 1987; 5: 1348-1355.
25. Ringden O, Hermans J, Labopin M et al. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia Lymphoma 1996; 24: 71-79.
26. Ringden O, Labopin M, Gluckman E et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis Acute. Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996; 18: 921-929.
27. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663-668.
28. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
29. Hongeng S, Krance RA, Bowman LC et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997; 350: 767-771.
30. Kondo M, Kojima S, Horibe K et al. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant 2001; 27: 727-730.
31. Storb R, Prentice RL, Sullivan KM et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461-466.
32. Ringden O, Paulin T, Lonnqvist B and Nilsson B. An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol 1985; 13: 1062-1067.
33. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
34. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
35. Saarinen-Pihkala UM, Gustafsson G, Ringden O et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001; 19: 3406-3414.
36. Ringden O, Labopin M, Gorin NC et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol 2000; 111: 1130-1137.
37. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leukemia Lymphoma 2000; 38: 221-234.
38. Dolstra H, Fredrix H, van der Meer A et al. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant 2001; 27: 1087-1093.
39. Mutis T, Goulmy E. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol 2002; 39: 23-31.